BTEK.LSE iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
- Total assets
- 447M
- Expense ratio
- 0.34%
- Dividend yield
- -
- 1-year return
- +37.29%
- Holdings
- 248
- Since
- 2017
Fund data as reported by the issuer, updated Nov 2, 2026. Total assets are in the fund's base currency.
What does BTEK.LSE invest in?
Tracks Morningstar Gbl Biotechnology NR USD- Mostly US stocks (94.0%)
- Largest sector: Healthcare (100.0%)
- Largest region: North America (91.3%)
- Top 3 holdings: 25.6% of the fund
Asset allocation
- US stocks 94.0%
- Non-US stocks 4.8%
- Cash 0.2%
Top holdings
- Amgen Inc 8.71%
- Gilead Sciences Inc 8.68%
- Vertex Pharmaceuticals Inc 8.19%
- Regeneron Pharmaceuticals Inc 6.07%
- Moderna Inc 5.82%
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) performance
Sharpe ratio 0.00- This year
- +28.05%
- 1 year
- +37.29%
- 3 years
- +26.78%
- 5 years
- +8.70%
Volatility 15.7% over 1 year and 17.0% over 3 years. Moderate, similar to a broad stock index.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
BTEK.LSE price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index.
Full fund profileiShares Nasdaq US Biotechnology UCITS ETF USD (Acc) top holdings
48.4% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Amgen Inc AMGN.US | Healthcare | United States | 8.71% |
| Gilead Sciences Inc GILD.US | Healthcare | United States | 8.68% |
| Vertex Pharmaceuticals Inc VRTX.US | Healthcare | United States | 8.19% |
| Regeneron Pharmaceuticals Inc REGN.US | Healthcare | United States | 6.07% |
| Moderna Inc MRNA.US | Healthcare | United States | 5.82% |
| Revolution Medicines Inc RVMD.US | Healthcare | United States | 2.48% |
| Biogen Inc BIIB.US | Healthcare | United States | 2.43% |
| Illumina Inc ILMN.US | Healthcare | United States | 2.29% |
| Royalty Pharma Plc RPRX.US | Healthcare | United States | 1.95% |
| Roivant Sciences Ltd ROIV.US | Healthcare | United States | 1.76% |
The 10 largest of 248 holdings.
BTEK.LSE sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
BTEK.LSE regional exposure
- North America91.3%
- Europe Developed2.3%
- United Kingdom2.1%
- Asia Emerging0.1%
- Australasia0.1%
- Africa/Middle East0.0%
- Asia Developed0.0%
Share of the stocks in the fund.
Company size
Average market cap 27.3B- Mega cap0.6%
- Big cap26.4%
- Medium cap34.5%
- Small cap26.5%
- Micro cap11.4%
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) fund profile
- Fund name
- iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
- Ticker
- BTEK.LSE
- Exchange
- London Exchange
- Index tracked
- Morningstar Gbl Biotechnology NR USD
- Category
- Healthcare Equity
- Domicile
- Ireland
- Inception date
- Oct 19, 2017
- Trading currency
- GBP
- Expense ratio
- 0.34%
About iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index.